Biohaven touts surge in Nurtec sales ahead of Pfizer takeover

Forget buyer’s remorse, Pfizer is likely feeling pretty good about its $11.6 billion Biohaven takeover deal following reports of a 57% sales boost for migraine med Nurtec.

Biohaven reported in Q2 results on Friday that it’s cleared the necessary antitrust hurdles to move forward with the sale of its calcitonin gene-related peptide (CGRP) assets to Pfizer. However, because the company is “focused on workstreams related to the closing” of the deal, it did not host a call with analysts and investors.

The company’s stock $BHVN was down less than 1% on Friday, pricing in at $146.96 per share.

The Pfizer deal is expected to close by “early 2023,” according to a news release. Aside from snagging the blockbuster migraine drug, Pfizer also gets zavegepant, an intranasal migraine therapy, and five preclinical assets in the deal covering the CGRP portfolio.

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.